| pubmed-article:21470196 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C0006413 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C1120843 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:21470196 | lifeskim:mentions | umls-concept:C1527240 | lld:lifeskim |
| pubmed-article:21470196 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:21470196 | pubmed:dateCreated | 2011-5-10 | lld:pubmed |
| pubmed-article:21470196 | pubmed:abstractText | Drug resistance and associated immune deregulation limit use of current therapies in chronic lymphocytic leukaemia (CLL), thus warranting alternative therapy development. Herein we demonstrate that OSU-DY7, a novel D-tyrosinol derivative targeting p38 mitogen-activated protein kinase (MAPK), mediates cytotoxicity in lymphocytic cell lines representing CLL (MEC-1), acute lymphoblastic leukaemia (697 cells), Burkitt lymphoma (Raji and Ramos) and primary B cells from CLL patients in a dose- and time-dependent manner. The OSU-DY7-induced cytotoxicity is dependent on caspase activation, as evidenced by induction of caspase-3 activation and poly (ADP-ribose) polymerase (PARP) cleavage and rescue of cytotoxicity by Z-VAD-FMK. Interestingly, OSU-DY7-induced cytotoxicity is mediated through activation of p38 MAPK, as evidenced by increased phosphorylation of p38 MAPK and downstream target protein MAPKAPK2. Pretreatment of B-CLL cells with SB202190, a specific p38 MAPK inhibitor, results in decreased MAPKAPK2 protein level with concomitant rescue of the cells from OSU-DY7-mediated cytotoxicity. Furthermore, OSU-DY7-induced cytotoxicity is associated with down regulation of p38 MAPK target BIRC5, that is rescued at protein and mRNA levels by SB202190. This study provides evidence for a role of OSU-DY7 in p38 MAPK activation and BIRC5 down regulation associated with apoptosis in B lymphocytic cells, thus warranting development of this alternative therapy for lymphoid malignancies. | lld:pubmed |
| pubmed-article:21470196 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21470196 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21470196 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21470196 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21470196 | pubmed:issn | 1365-2141 | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:ByrdJohn CJC | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:KulpSamuel... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:ChenChing-Shi... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:MuthusamyNata... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:ChiuChang-Fan... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:MoXiaokuiX | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:FrissoraFrank... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:BaiLi-YuanLY | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:JarjouraDavid... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:WangShu-HueiS... | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:MaYihuiY | lld:pubmed |
| pubmed-article:21470196 | pubmed:author | pubmed-author:ManiRajeswara... | lld:pubmed |
| pubmed-article:21470196 | pubmed:copyrightInfo | © 2011 Blackwell Publishing Ltd. | lld:pubmed |
| pubmed-article:21470196 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21470196 | pubmed:volume | 153 | lld:pubmed |
| pubmed-article:21470196 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21470196 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21470196 | pubmed:pagination | 623-33 | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:meshHeading | pubmed-meshheading:21470196... | lld:pubmed |
| pubmed-article:21470196 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21470196 | pubmed:articleTitle | OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway. | lld:pubmed |
| pubmed-article:21470196 | pubmed:affiliation | Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan. | lld:pubmed |
| pubmed-article:21470196 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21470196 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21470196 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
